Insecticides India Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fp5fp9am5q034u3opg080rs9.pdf

Key Takeaways


Premiumization Strategy & Product Portfolio

Rajesh Aggarwal: "The product becomes profitable from day 1. So there is no gestation period for a profitable product because if you are launching something in the Maharatna segment, focused Maharatna segment, you are very, very clear that it has to qualify the minimum gross margin of 35%."

Margin & Profitability

Rajesh Aggarwal: "The premiumization strategy has played out very well. The effort to make it is in full swing, and we are continuously working around these new products, which is responsible for increasing the profitability of this quarter and taking it to 42%, though this is a lean quarter and we cannot take it as a full year number."

Price Environment & Raw Material

Rajesh Aggarwal: "The prices have touched the bottom already and they have started going up. As the prices goes up, the market prices are also going to go up because it is going to increase for everyone."

Capacity Expansion & Capex

Rajesh Aggarwal: "So in terms of number, I can say that if it achieves even 65%, 70%, it will be crossing INR500 crores in the first year itself, first full year."

Biologicals & New Initiatives

Rajesh Aggarwal: "It is a very futuristic business actually. So we are applying for a lot of patents, and we are working on R&D of biological products in many new ways. So these are secret things. I cannot declare too much."

Organization & Acquisitions

Rajesh Aggarwal: "Kaeros gives the opportunity to import these technicals, which we generally purchase from our competition at a little higher price. So it will improve the profitability of the company."

Guidance & Commitments

CommitmentSpecificsTimeline
Premium product mixGrow to 65% of B2C from current 62%Next 1-2 years
Premium product volume growthMinimum 20% YoY volume growth in B2C premium products every yearContinuous target for next 4-5 years
Gross marginReach 30% to 35%Next 1-2 years
EBITDA marginAchieve about 12% to 13%Implied medium-term
Working capitalImprove cycle by at least 20-25 daysNext year
New product launchesAt least more than half a dozen products, all qualifying in Maharatna segmentNext fiscal year
Seaweed product salesCross at least 1 lakh litersFY26
Seaweed long-term revenueGenerate INR50-70 crores, become brand leader4-5 years
Sotanala plant startPlant to begin operations2026
Sotanala first full year revenueCross INR500 crores at 65-70% utilizationFirst full year after start
CapexINR125 crores, majority in next fiscalNext 2 years
Kaeros plansReady with plansBy next investor call

Key Metrics

MetricQ3 FY25
Revenue from operations₹358 cr, YoY growth ~18%
9M FY25 revenue from operations₹1,641 cr
EBITDA₹61 cr, up from ₹24 cr in Q3 FY24
EBITDA margin8.6%
9M FY25 EBITDA₹193 cr, margin 11.7%
PAT₹17.4 cr, YoY growth ~42%
9M FY25 PAT₹128 cr, YoY growth ~36%, highest in company history
B2C sales contribution82% of total sales
B2B sales contribution11% of total sales
Exports contribution7% of total sales
Premium products share of B2C sales55% in Q3, 62% in 9M FY25
Product mix: Insecticides49% of total sales
Product mix: Herbicides37% of total sales
Product mix: Fungicides9% of total sales
B2C volume growth~7-8% YoY
Premium products volume growth (9M)~19% YoY
Premium products value growth (9M)~12% YoY
Capex planned₹125 cr over next 2 years, majority in next fiscal
Sotanala plant revenue potential at 65-70% capacityCrossing ₹500 cr in first full year
New product launches in current fiscal10
New launches planned for next fiscalAt least 6, plus possible biological additions
Focus Maharatna products currently11, targeting 15
Export revenue guidance for FY25Crossing ₹100 cr, below earlier target of ₹150 cr
Kaeros acquisition cost₹6.3 cr, including land and business value
Seaweed biological product FY26 sales targetAt least 1 lakh liters, ~₹10 cr
Distributor network increase expected~4-5%